A study on ccRCC demonstrated that the abundance of intratumoral CD8+T cells secreting CXCL13 was associated with increased TLS and immunoevasive TME, functioning as a potential immunotherapeutic marker for ccRCC treatment (37). This evidence concerns the gene CXCL13 and nonpapillary renal cell carcinoma.